

August 06, 2019

Share price movers - July 2019



[Edwin Elmhirst](#)

Biggest share price movements – July 2019

Top Gains

+147%

Silence Therapeutics

Mallinckrodt licenses worldwide rights to SLN500, with options on up to two additional assets. Silence to receive \$20m up front, and up to \$1.4bn in milestones

+82%

SC Pharmaceuticals

Company says the FDA has indicated it should not be necessary to conduct additional clinical studies as part of Furoscix's NDA.

+80%

Oasmia Pharmaceutical

Enters into agreement with its largest shareholder, Arwidsro, to fulfil financing obligation of \$7.83m early, to solve company's outstanding balance issues.

+68%

Mezzion Pharma

Reports positive top-line result from phase III Fuel trial of its congenital heart disease candidate, udenafil.

+65%

Achillion Pharmaceuticals

Reports phase I data suggesting greater potency with its next-generation complement inhibitor.

-52%

Amneal Pharmaceuticals

Lowers 2019 earnings forecast, citing competition, launch delays and supply uncertainties with epinephrine auto-injectors; also announces restructuring.

-53%

Canntrust

Health Canada issues non-compliance report after finding company had been growing cannabis in unlicensed rooms.

-60%

Polyphor

Ends the phase III Prism MDR and UDR studies of murapavadin IV which had been put on voluntary hold in May 2019.

-73%

Marinus Pharmaceuticals

Reports disappointing results with oral ganaxolone in second part of Magnolia phase II trial in women with postpartum depression.

-79%

Lexicon Pharmaceuticals

Sanofi issues a notice to terminate licensing deal for Zynquista after disappointing results from two phase III trials; Lexicon disputes grounds for termination.

Top Losses

Vantage

Market cap movement of at least \$30m

[More from Evaluate Vantage](#)

Evaluate HQ

[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas

[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC

[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2023 Evaluate Ltd.